ArticleProbiotics and antimicrobial proteins2026
Safety Evaluation of Human-Derived Uric Acid Degrading Lacticaseibacillus paracasei M2a and Its Impact on Gut Microbiota.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Gut microbiota-mediated uric acid metabolism: Novel insights for developing urate-lowering and anti-gout medications.Pharmaceutical science advances · 2026Review
- Cold-Adapted Uric Acid-DegradingMolecules (Basel, Switzerland) · 2026Article
- Oral supplementation ofApplied and environmental microbiology · 2026Article
- GPR109a-AMPK axis mediates the Attenuation of uric acid-induced M1 macrophage polarization by β-hydroxybutyrate from Lacticaseibacillus rhamnosus M2b.Scientific reports · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
We report the identification of a human-derived uric acid (UA)-degrading bacterial strain, analyzed its degradation efficiency, and assessed its safety to provide a scientific basis for future clinical applications in the treatment of hyperuricemia (HUA) and gout. Here, we isolated the M2a strain from feces of healthy young men. The strain was identified as Lacticaseibacillus paracasei (formerly Lactobacillus paracasei) via 16S rRNA and biochemical analyses. The in vitro and in vivo efficiencies of M2a uric acid degradation were found to be 45.53% and up to 47.88%, respectively. Strain M2a exhibited no detectable pathogenicity, demonstrated robust tolerance to simulated gastrointestinal conditions, and displayed a favorable safety profile. The strain ameliorated hyperuricemia-associated liver and kidney dysfunction, as evidenced by improved biochemical markers (ALT, AST, BUN, and CRE; P < 0.05) and histopathological findings showing reduced inflammatory cell infiltration and preserved tissue architecture in HE-stained liver and kidney sections. Furthermore, it regulated intestinal microbiota in HUA mice, increased the relative content of beneficial bacteria (e.g., Lacticaseibacillus) in the mouse intestine, and reduced the intestinal presence of Klebsiella and Blautia in mice. Further study of M2a is warranted to elucidate pathways for lowering blood levels of uric acid via clinical utilization of probiotic and associated biologic interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.